CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation Clinical Risk Factors and Atherosclerotic Plaque Extent to Define Risk for Major Events in Patients Without Obstructive Coronary Artery Disease: The Long-Term Coronary Computed Tomography Angiography CONFIRM Registry Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study Mechanisms of Vascular Aging, A Geroscience Perspective JACC Focus Seminar Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease Prognostic implications of ischemia with nonobstructive coronary arteries (INOCA): Understanding risks for improving treatment Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

LetterJune 2, 2020 Vol 141, Issue 22

JOURNAL:Circulation. Article Link

Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation

SC Larsson, D Gill , AM Mason et al. Keywords: Lipoprotein(a); causal effect; CAD; valvular disease

Full Text PDF